Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment

Genetics Investing

Mesoblast (Nasdaq:MESO) announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal injection of its proprietary allogeneic mesenchymal precursor cell (MPC) product candidate MPC-06-ID in patients with chronic low back pain due to degenerative disc disease. As quoted in the press release: MPC-06-ID is being evaluated to determine whether it can alleviate pain …

As quoted in the press release:

MPC-06-ID is being evaluated to determine whether it can alleviate pain and improve function in patients who do not receive adequate relief from current standard of care therapies such as non-steroidal anti-inflammatory drugs, epidural steroid injections or opioids.
The 2:1 randomized, placebo-controlled Phase 3 trial (NCT02412735) enrolled 404 patients across 48 centers in the United States and Australia. Following completion of the planned enrollment of 360 patients, all additional patients still in screening at that point were allowed to complete enrollment.

Click here to read the full press release.

australia disease enrollment injection mesoblast pain patients phase 3 trial product candidate united states Genetics Investing